JPWO2022181797A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022181797A5 JPWO2022181797A5 JP2023502560A JP2023502560A JPWO2022181797A5 JP WO2022181797 A5 JPWO2022181797 A5 JP WO2022181797A5 JP 2023502560 A JP2023502560 A JP 2023502560A JP 2023502560 A JP2023502560 A JP 2023502560A JP WO2022181797 A5 JPWO2022181797 A5 JP WO2022181797A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- composition
- disorders
- inhibitor
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 36
- 206010012601 diabetes mellitus Diseases 0.000 claims 27
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 24
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 230000002159 abnormal effect Effects 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 210000000130 stem cell Anatomy 0.000 claims 12
- 230000012292 cell migration Effects 0.000 claims 11
- 208000024891 symptom Diseases 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 108090000353 Histone deacetylase Proteins 0.000 claims 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 8
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims 6
- 230000005012 migration Effects 0.000 claims 6
- 238000013508 migration Methods 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 5
- 230000002688 persistence Effects 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 4
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 108010027178 cyclic hydroxamic acid-containing peptide 1 Proteins 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960000556 fingolimod Drugs 0.000 claims 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108010091666 romidepsin Proteins 0.000 claims 2
- 229960003452 romidepsin Drugs 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- 229960000237 vorinostat Drugs 0.000 claims 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710085496 C-X-C motif chemokine 2 Proteins 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 108010029961 Filgrastim Proteins 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 108010062867 Lenograstim Proteins 0.000 claims 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 108010076181 Proinsulin Proteins 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 229930189037 Trapoxin Natural products 0.000 claims 1
- 102100038138 WD repeat-containing protein 26 Human genes 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 1
- 229960003094 belinostat Drugs 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 229960004177 filgrastim Drugs 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229950010415 givinostat Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229960002618 lenograstim Drugs 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 108010032539 nartograstim Proteins 0.000 claims 1
- 229950010676 nartograstim Drugs 0.000 claims 1
- 229960003278 osimertinib Drugs 0.000 claims 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims 1
- 108010044644 pegfilgrastim Proteins 0.000 claims 1
- 229960001373 pegfilgrastim Drugs 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims 1
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 108010060597 trapoxin A Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021030812 | 2021-02-26 | ||
| PCT/JP2022/008036 WO2022181797A1 (ja) | 2021-02-26 | 2022-02-25 | 糖尿病および合併症の新規治療、診断および検出のための方法および剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022181797A1 JPWO2022181797A1 (https=) | 2022-09-01 |
| JPWO2022181797A5 true JPWO2022181797A5 (https=) | 2024-01-31 |
Family
ID=83049251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502560A Pending JPWO2022181797A1 (https=) | 2021-02-26 | 2022-02-25 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240139129A1 (https=) |
| EP (1) | EP4299076A4 (https=) |
| JP (1) | JPWO2022181797A1 (https=) |
| KR (1) | KR20230152099A (https=) |
| CN (1) | CN117750976A (https=) |
| AU (1) | AU2022225981A1 (https=) |
| IL (1) | IL305464A (https=) |
| WO (1) | WO2022181797A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312393A (en) * | 2021-10-29 | 2024-06-01 | Biozipcode Inc | A method or factor with an HDAC regulator, for the treatment of diabetes and complications |
| CN118161493B (zh) * | 2024-05-14 | 2024-08-09 | 南昌大学第一附属医院 | 恩替诺特在制备治疗耐药非小细胞肺癌的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0671936A1 (en) * | 1992-10-15 | 1995-09-20 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION |
| AU2007271163B2 (en) * | 2006-07-06 | 2012-08-23 | Merck Serono Sa | CSF3R polypeptides and uses thereof |
| KR100812274B1 (ko) * | 2006-10-30 | 2008-03-13 | 한양대학교 산학협력단 | Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제 |
| EP2182976A4 (en) * | 2007-08-31 | 2012-01-25 | Massachusetts Inst Technology | TREATMENT OF AUTOIMMUNE DISEASES |
| JP2015024960A (ja) * | 2011-11-17 | 2015-02-05 | 公益財団法人東京都医学総合研究所 | Ｃｘｃｒ４活性阻害ペプチド及びその用途 |
| US10465003B2 (en) * | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
| JP2021030812A (ja) | 2019-08-21 | 2021-03-01 | 株式会社 商船三井 | 船舶 |
| CN114828890A (zh) * | 2019-10-18 | 2022-07-29 | 比奥兹普科德公司 | 使用了干细胞迁移剂的糖尿病治疗 |
-
2022
- 2022-02-25 KR KR1020237032953A patent/KR20230152099A/ko active Pending
- 2022-02-25 CN CN202280030689.5A patent/CN117750976A/zh active Pending
- 2022-02-25 US US18/548,023 patent/US20240139129A1/en active Pending
- 2022-02-25 AU AU2022225981A patent/AU2022225981A1/en not_active Abandoned
- 2022-02-25 WO PCT/JP2022/008036 patent/WO2022181797A1/ja not_active Ceased
- 2022-02-25 EP EP22759831.5A patent/EP4299076A4/en active Pending
- 2022-02-25 IL IL305464A patent/IL305464A/en unknown
- 2022-02-25 JP JP2023502560A patent/JPWO2022181797A1/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kinney | Metabolic responses of the critically ill patient | |
| Jeschke et al. | Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children | |
| Zhang et al. | More than an anti-diabetic bariatric surgery, metabolic surgery alleviates systemic and local inflammation in obesity | |
| Zhang et al. | Sodium butyrate prevents lethality of severe sepsis in rats | |
| JPWO2022181797A5 (https=) | ||
| JPWO2021075536A5 (https=) | ||
| Hussain et al. | Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies | |
| Guo et al. | Clinical efficacy of antibiotic-loaded bone cement and negative pressure wound therapy in multidrug-resistant organisms diabetic foot ulcers: a retrospective analysis | |
| Thompson et al. | The effectiveness of alpha-2-macroglobulin injections for osteoarthritis of the knee | |
| Lv et al. | Early sacral neuromodulation prevented detrusor overactivity in rats with spinal cord injury | |
| Derde et al. | Increasing intravenous glucose load in the presence of normoglycemia: effect on outcome and metabolism in critically ill rabbits | |
| Bennett et al. | Constant rate infusion of glucagon as an emergency treatment for hypoglycemia in a domestic ferret (Mustela putorius furo) | |
| Doganay et al. | Mesalazine-induced myopericarditis in a patient with ulcerative colitis | |
| EP3409271B1 (en) | Local anesthetics to facilitate food intake and food retention | |
| Dimos et al. | Delayed acute coronary syndrome caused by multiple bee stings: a rare case of Kounis syndrome | |
| M Halfaya et al. | Effect of Platelet-rich Plasma on MMP-13, ARE and TGF β1 in MIA-Induced Osteoarthritis in Rats | |
| Yang et al. | Suberoylanilide hydroxamic acid attenuates epidural fibrosis via inhibiting myofibroblast differentiation and increasing fibroblast apoptosis. | |
| US20130129670A1 (en) | Macrophage activating factor for use in the treatment of chronic fatigue syndrome (cfs) and cfs-related diseases and disorders | |
| Shi-Nan et al. | Microglial voltage-dependent anion channel 1 signaling modulates sleep deprivation-induced transition to chronic postsurgical pain | |
| Kanbay et al. | Chronodisruption: A Poorly Recognized Feature | |
| Baumwart et al. | Effects of hyperbaric oxygen treatment on horses with experimentally induced endotoxemia | |
| CN116265016B (zh) | 癫痫疾病药物的组合物及其用于制备治疗癫痫疾病药物的用途 | |
| RU2675180C1 (ru) | Способ определения степени травматичности симультанного оперативного вмешательства | |
| Grijalva | Tame the flame: Inflammation is a targetable physiological mechanism underlying poor outcomes of heat stress in finishing sheep | |
| Shankar | COMPLICATIONS OF “THE FIRST MIRACLE DRUG”–INSULIN |